Relmada Therapeutics, Inc.

Targeting Major Advances in Treatment of CNS Disorders

Relmada Therapeutics addresses areas of high unmet needs in depression, CNS and ophthalmological disorders.

Who We Are

Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders.

Learn More About Relmada Therapeutics

Our Drug Candidates

REL-1017 (dextromethadone)

Novel NMDA receptor antagonist in Phase 2 clinical testing for the treatment of depression, and preclinical development for Rett syndrome and other indications.

View REL-1017 (d-Methadone)

505(b)2 Drug Candidates

REL-1015 (LevoCap ER)

Extended release, abuse resistant form of broad spectrum opioid levorphanol for treatment of chronic pain when an opioid is needed.

View REL-1015 (LevoCap ER)

REL-1028 (BuTab)

Novel oral formulations of modified release buprenorphine being developed for both chronic pain and opioid dependence indications.

View REL-1028 (BuTab)

REL-1021 (MepiGel)

Topical gel dosage form of local anesthetic mepivacaine for treatment of postherpetic neuralgia (PHN) and HIV-associated neuropathy.

View REL-1021 (MepiGel)

Our Leadership

Our efforts are guided by highly experienced drug development leadership and world-class scientific advisors that provide the expertise to efficiently advance product development.